How Guidant's Poor CAPA System Played A Role In Device Troubles
This article was originally published in The Silver Sheet
Executive Summary
GUIDANT HAD TOO MANY CAPA SYSTEMS and quality data databases that failed to link together. This problem helped lead to the now-defunct company's numerous recalls of implantable cardioverter defibrillators and pacemakers in 2005, an ex-employee says
You may also be interested in...
Conduct CAPA Activities Appropriately, FDA Warns Manufacturers
CORRECTIONS, CORRECTIVE ACTIONS AND PREVENTIVE ACTIONS are not being applied correctly by manufacturers, FDA says. "Corrections are spot fixes for a particular product or issue [and] are followed by corrective actions, which are more systemic," says FDA/GMP expert Kim Trautman. Further, she often sees "so many things called 'preventive actions' that aren't preventive actions." A Global Harmonization Task Force draft guidance on the topic may clear up industry confusion. It details a four-part approach that companies can use when launching a CAPA system, including identifying quality data sources, analyzing data, conducting investigations and keeping top management informed. Device firms Becton Dickinson (BD) and AGA Medical also explain how they apply risk management principles to determine whether product problems should be elevated to their CAPA systems
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?
Thumbs Up: FDA Authorizes Weight Loss Suturing Systems From Apollo Endosurgery
People with obesity now have new tools to help them lose weight, thanks to the US agency’s de novo authorization.